clementia

**PFIC ANNUAL INFORMATION STATEMENT**
**CLEMENTIA PHARMACEUTICALS INC.**

This Information Statement is for the taxable year of Clementia Pharmaceuticals Inc. (the ***Corporation***) beginning on January 1, 2018 and ending on December 31, 2018 (the ***Taxable Year***) and is issued to the Corporation's Investors and their Partners.

For the Taxable Year, the Corporation:

**X** was a passive foreign investment company ("PFIC").

____ was not a PFIC (skip earning and distribution sections).

Investor's pro-rata share of the Corporation's ordinary earnings and net capital gain (as determined under U.S. federal income tax principles) for the Taxable Year follows:

| | |
|---|---|
| Ordinary Earnings[1] | $nil |
| Net Capital Gains | $nil |

The amount of cash and fair market value of other property distributed or deemed distributed by the Corporation to Investor during the Taxable Year was:

| | |
|---|---|
| Cash | $nil |
| Fair Market Value of Property | $nil |

In accordance with Treasury Regulation Section 1.1295-1(g)(1)(iv), the Corporation will permit Investors and their direct or indirect owners to inspect and copy the Corporation's permanent books of accounts, records and other such Corporation documents as are necessary to establish that the Corporation's ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. income tax principles.

Date: March 11, 2019

CLEMENTIA PHARMACEUTICALS INC.

By: /s/ Steve Forte
Steve Forte, Chief Financial Officer

1. The term "ordinary earnings" means the excess of the earnings and profits of the qualified electing fund (QEF) for the taxable year over its net capital gain for the taxable year.